Eliem Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Co. is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver therapeutics for patients with these disorders. Co.'s two clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide prodrug for the treatment of diabetic peripheral neuropathic pain and lumbosacral radicular pain, commonly referred to as sciatica. The ELYM stock yearly return is shown above.
The yearly return on the ELYM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ELYM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|